Caris Life Sciences (CAI) Net Margin (2024 - 2026)

Caris Life Sciences' Net Margin history runs 3 years deep, the most recent figure standing at 0.24% for Q1 2026.

• In Q1 2026, Net Margin rose 10483.0% year-over-year to 0.24%; the TTM figure through Mar 2026 stood at 45.35% (up 3668.0% YoY), while the FY2025 annual figure was 66.25%, up 2550.0% from the prior year.
• Net Margin for Q1 2026 stood at 0.24%, down from 27.98% in the prior quarter.
• The five-year high for Net Margin was 27.98% in Q4 2025, with the low at 285.12% in Q2 2025.
• The 3-year median for Net Margin is 68.71% (2024), against an average of 72.44%.
• The sharpest annual moves came in 2025 and 2026: Net Margin sank 19538 bps in 2025, then surged 10483 bps in 2026.
• Caris Life Sciences' Net Margin stood at 47.68% in 2024, then surged by 159 bps to 27.98% in 2025, then slumped by 101 bps to 0.24% in 2026.
• Business Quant data shows CAI's Net Margin at 0.24% in Q1 2026, 27.98% in Q4 2025, and 11.22% in Q3 2025.